In the fall of 2018, the 2.5-mg dose of the name-brand rivaroxaban was introduced to the U.S., when it was approved for prevention of major adverse cardiovascular events in CAD and PAD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback